Stockreport
Moleculin Biotech files to sell 6.37M shares of common stock for holders [Seeking Alpha]
Last moleculin biotech, inc. earnings: 8/16 05:35 pm
Check Earnings Report
US:NASDAQ Investor Relations: moleculin.com/investors
The company will not receive any proceeds from the sale of common stocks by the selling shareholder. MBRX down by 6.56%. Filing. Fresh Stock Ideas, Every Day More on Moleculin Biotech Moleculin Biotech secures $8.3M from warrant exercises, issues new 5-year warrants Seeking Alpha's Quant Rating on Moleculin Biotech Historical earnings data for Moleculin Biotech Financial information for Moleculin Biotech Recommended For You More Trending News
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | MBRX | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
MBRX alerts
MBRX alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
MBRX alerts
High impacting Moleculin Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
MBRX
NEWS
NEWS
- Moleculin Releases Next CEO Corner Segment Highlighting Annamycin’s Non-Cardiotoxic Profile[GlobeNewswire]
- Moleculin Biotech (MBRX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $22.00 price target on the stock.[MarketBeat]
- Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout [Yahoo! Finance][Yahoo! Finance]
- Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout[GlobeNewswire]
- Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026 [Yahoo! Finance][Yahoo! Finance]
- More
MBRX
SEC Filings
SEC Filings
- 3/27/26 - Form S-3
- 3/23/26 - Form 8-K
- 3/19/26 - Form 8-K
- MBRX's page on the SEC website
- More